The V3 loop of the HIV-1 envelope (Env) glycoprotein gp120 was identified as the “principal neutralizing domain” of HIV-1, but has been considered too variable to serve as a neutralizing antibody (Ab) target. Structural and immunochemical data suggest, however, that V3 contains conserved elements which explain its role in binding to virus co-receptors despite its sequence variability. Despite this evidence of V3 conservation, the ability of anti-V3 Abs to neutralize a significant proportion of HIV-1 isolates from different subtypes (clades) has remained controversial.), and was statistically assessed based on the area under the neutralization titration curves (AUC). criteria, 40/98 (41%) psVs were neutralized by ≥1 anti-V3 mAbs.Using standa...
HIV-1 neutralizing monoclonal antibodies (MAbs) define key targets for vaccine development and are b...
Funder: Swiss government (through SERI) under grant agreement No.15.0337. Gilead HIV-1 Cure Grant 40...
AbstractRabbits were immunized with a novel regimen designed to focus the immune response on a singl...
The V3 loop of the HIV-1 envelope (Env) glycoprotein gp120 was identified as the “principal neutrali...
The V3 loop of the HIV-1 envelope (Env) glycoprotein gp120 was identified as the "principal neutrali...
AbstractThe identification of cross-neutralizing antibodies to HIV-1 is important for designing anti...
Human monoclonal antibody 447-52D binds to the V3 determinant of the human immunodeficiency virus ty...
The major target of the neutralizing antibody response to infection by the human immunodeficiency vi...
AbstractThe HIV-1 gp120 V3 loop is a potent inducer of neutralizing antibodies for T cell line adapt...
<p>V3 positive mAbs 10A37 and 10A3 were tested for neutralization against pseudoviruses belonging to...
Abstract The V3 region of both HIV-1 gp120 and HIV-2 gp125 surface glycoprotein has been described a...
The third variable region, V3, of the gp120 surface envelope glycoprotein is an approximately 35-res...
The principal neutralizing domain (PND) of HIV-1, located within the third variable region (V3) of t...
AbstractThe identification of cross-neutralizing antibodies to HIV-1 is important for designing anti...
The principal neutralizing domain (PND) of HIV-1, located within the third variable region (V3) of t...
HIV-1 neutralizing monoclonal antibodies (MAbs) define key targets for vaccine development and are b...
Funder: Swiss government (through SERI) under grant agreement No.15.0337. Gilead HIV-1 Cure Grant 40...
AbstractRabbits were immunized with a novel regimen designed to focus the immune response on a singl...
The V3 loop of the HIV-1 envelope (Env) glycoprotein gp120 was identified as the “principal neutrali...
The V3 loop of the HIV-1 envelope (Env) glycoprotein gp120 was identified as the "principal neutrali...
AbstractThe identification of cross-neutralizing antibodies to HIV-1 is important for designing anti...
Human monoclonal antibody 447-52D binds to the V3 determinant of the human immunodeficiency virus ty...
The major target of the neutralizing antibody response to infection by the human immunodeficiency vi...
AbstractThe HIV-1 gp120 V3 loop is a potent inducer of neutralizing antibodies for T cell line adapt...
<p>V3 positive mAbs 10A37 and 10A3 were tested for neutralization against pseudoviruses belonging to...
Abstract The V3 region of both HIV-1 gp120 and HIV-2 gp125 surface glycoprotein has been described a...
The third variable region, V3, of the gp120 surface envelope glycoprotein is an approximately 35-res...
The principal neutralizing domain (PND) of HIV-1, located within the third variable region (V3) of t...
AbstractThe identification of cross-neutralizing antibodies to HIV-1 is important for designing anti...
The principal neutralizing domain (PND) of HIV-1, located within the third variable region (V3) of t...
HIV-1 neutralizing monoclonal antibodies (MAbs) define key targets for vaccine development and are b...
Funder: Swiss government (through SERI) under grant agreement No.15.0337. Gilead HIV-1 Cure Grant 40...
AbstractRabbits were immunized with a novel regimen designed to focus the immune response on a singl...